Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1
media
posted on 2023-09-21, 22:45 authored by Adis journals on behalf of, Eric L. Simpson, Andrew Blauvelt, Jonathan I. Silverberg, Michael J. Cork, Norito Katoh, Thomas Mark, Shannon K.R. Schneider, Andreas Wollenberg<p><strong>Article full text</strong></p>
<p>The above video abstract and key points represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2023</p>
